Company news
Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A (SSE:603707) news
Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Sep 30, 2026: "Nanjing King-Friend Biochemical Pharmaceutical…
View Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A →
Press releases & updates
"Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd."Announcement on Obtaining U.S. FDA Approval for Adalimumab Injection of Subsidiary
September 29, 2026
"Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd."Announcement on Obtaining U.S. FDA Approval for Vitamin B1 Injection of Subsidiary
September 28, 2026
"Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd."Announcement on Participation in Subscription of Private Fund Units by Wholly-owned Subsidiary
September 24, 2026
"Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd."Announcement on Subsidiary's Receipt of U.S. FDA Approval for an Additional Manufacturing Site for Amikacin Sulfate Injection
September 22, 2026
"Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd."Announcement on Subsidiary's Receipt of U.S. FDA Approval for an Additional Manufacturing Site for Adalimumab Injection
September 1, 2026
"Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd."Announcement on Change in Accounting Policies
August 27, 2026
"Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd."Announcement on the U.S. FDA Approval of the Subsidiary's Insulin Aspart Injection
July 27, 2026
"Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd."Announcement on Obtaining the Drug Registration Approval for Propofol Emulsion Injection by the National Medical Products Administration
July 6, 2026
"Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd."Announcement on the Subsidiary's Receipt of the U.S. FDA Approval for the Manufacturing Site Transfer Registration of Desmopressin Acetate Injection
July 3, 2026
Announcement on Implementation of Dividend Distribution for 2025
June 2, 2026
Announcement on Resolutions of the 1st Meeting of the 6th Board of Directors
May 20, 2026
Announcement on Implementation Result of Shares Repurchase and Share Changes
May 11, 2026
Announcement on Progress in Repurchasing Shares
May 6, 2026
Announcement on Convening Performance and Cash Dividend Meeting for 2025 and Q1 2026
May 5, 2026
Announcement on Proposing of Purchasing Liability Insurance for the Company and Directors, and Senior Management Members
April 29, 2026
Announcement on Maturity and Redemption of "KING-FRIEND Convertible Bonds" and Delisting
April 14, 2026
Announcement on the Conversion Results and Stock Changes of ""Jianyou Convertible Bonds"
April 1, 2026
The 3rd Indicative Announcement on Maturity and Redemption of "King-Friend Convertible Bonds" and Delisting
March 23, 2026
The 2nd Indicative Announcement on Maturity and Redemption of "King-Friend Convertible Bonds" and Delisting
March 19, 2026
The 1st Indicative Announcement on Maturity and Redemption of "King-Friend Convertible Bonds" and Delisting
March 17, 2026
Announcement on Subsidiary Obtaining the Registration Approval Letter for Drug Production Site Transfer of Lafamulin Injection from FDA of the United States
February 26, 2026
Announcement on Obtaining FDA Approval by Subsidiary for Sodium Selenite Injection
February 4, 2026
Announcement on Completing Industrial and Commercial Change Registration
January 29, 2026
Indicative Announcement on the Proposed Reversal of Inventory Impairment
January 28, 2026
Announcement on Not Revising Downward Conversion Price of ""King-friend Convertible Bonds"
December 12, 2025
Indicative Announcement on the Expected Fulfillment of Conversion Price Amendment Conditions for ""King-Friend Convertible Bonds"
December 5, 2025
Announcement on Obtaining FDA Approval by Subsidiary for Propofol Injectable Emulsion
December 3, 2025
Announcement on Approval of Subsidiary's Product Dalbavancin for Injection by the U.S. FDA
November 27, 2025
Announcement on Election of Employee Representative Directors for the 5th Board of Directors
November 12, 2025
Announcement on Subsidiary's Acquisition of U.S. FDA Approval for Additional Production Site of Vecuronium Bromide for Injection
November 10, 2025
Announcement on Voluntary Disclosure of Nadroparin Calcium Injection Passing Consistency Evaluation of Quality and Efficacy of Generic Drugs
November 6, 2025
Announcement on Subsidiary Obtaining FDA New Drug Approval for Fosfomycin for Injection
October 24, 2025
Announcement on the Conversion Results and Stock Changes of "Jianyou Convertible Bonds"
October 9, 2025
Semi-annual Evaluation Report on "Corporate Value and Return Enhancement" Action Plan 2025
August 28, 2025
Announcement on Obtaining the US FDA Drug Registration Approval for Nicardipine Hydrochloride Injection
August 21, 2025
Announcement on Subsidiary's Approval from U.S. FDA for Production Site Transfer of Etoposide Injection
July 22, 2025
Announcement on Follow-up Rating Results of Convertible Corporate Bonds in 2025
June 27, 2025
Announcement on Results of Optional Sell-back of "King-Friend Convertible Bonds"
June 25, 2025
The 9th Indicative Announcement on Optional Sell-back of "King-Friend Convertible Bonds"
June 22, 2025
The 8th Indicative Announcement on Optional Sell-back of "King-Friend Convertible Bonds"
June 19, 2025
The 7th Indicative Announcement on Optional Sell-back of "King-Friend Convertible Bonds"
June 18, 2025
The 6th Indicative Announcement on Optional Sell-back of "King-Friend Convertible Bonds"
June 17, 2025
The 5th Indicative Announcement on Optional Sell-back of "King-Friend Convertible Bonds"
June 16, 2025
The 4th Indicative Announcement on Optional Sell-back of "King-Friend Convertible Bonds"
June 15, 2025
The 3rd Indicative Announcement on Optional Sell-back of "King-Friend Convertible Bonds"
June 12, 2025
The 2nd Indicative Announcement on Optional Sell-back of "King-Friend Convertible Bonds"
June 11, 2025
The 1st Indicative Announcement on Optional Sell-back of "King-Friend Convertible Bonds"
June 10, 2025
Announcement on Optional Sell-back of "King-Friend Convertible Bonds"
June 9, 2025
Announcement on Obtaining FDA Approval by Subsidiary for Hydralazine Hydrochloride Injection
June 4, 2025
Announcement on Adjustment of Conversion Price for "King-Friend Convertible Bonds"
May 28, 2025